Case series of severe intoxications associated with new psychoactive substances on Reunion Island: clinical description and diagnostic challenges - 31/01/25







Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Background: New psychoactive drugs appeared in Reunion Island beginning in 2016, principally synthetic cannabinoids such as “tabac chimique”. We described the clinical features of twelve hospitalizations during 2023-2024 requiring admission to intensive care unit for suspected psychoactive drug intoxication with atypical clinical presentation for synthetic cannabinoids, including a morphine-like toxidrome
Results: Over a ten-month period, twelve patients aged from 21 to 43 years required treatment in the intensive care unit with a suspected psychoactive drug intoxication. The main cause of intensive care unit admission was a profound coma with early acute respiratory failure. All patients except one developed acute respiratory distress syndrome, with six being severe and ten requiring intubation with mechanical ventilation. Four patients experienced hemodynamic hock.
Five exhibited acute heart failure, with three requiring inotropic drugs. Five patients developed acute renal failure and one patient developed acute liver failure. Most of the patients confirmed inhaling “tabac chimique”. Two blood and urine samples were positive for the novel synthetic opioid Protonitazene, one was associated with a novel synthetic cannabinoid. Another analysis was positive for a metamphetamine analogue.
Conclusions: Inhalation of new psychoactive substances including novel synthetic opioids can lead to severe organ failure with a life-threatening prognosis, with neurological and respiratory failure initially, followed by early acute cardiac failure.
Le texte complet de cet article est disponible en PDF.Keywords : new synthetic drugs, severe intoxication, acute synthetic opioid toxicity, opioid-induced acute respiratory distress syndrome, opioid-induced acute cardiac heart failure, Protonitazene, Indian Ocean, Benzimidazole 47
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?